Search
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigationalPancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms.
Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly. … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation.
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Propafenone
go.drugbank.com/drugs/DB01182ApprovedInvestigationalAn antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing … VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target.
Digitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.
Categories: Compounds used in a research, industrial, or household settingFosdenopterin
go.drugbank.com/drugs/DB16628Approved[A230088] MoCD is incurable and median survival in untreated patients is approximately 36 months[A230088] - treatment, then, is focused on improving survival and maintaining neurological function. … [L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433]
Prednisone
go.drugbank.com/drugs/DB00635ApprovedInvestigationalVet approved[A187463] It is biologically inert and converted to [prednisolone] in the liver.[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496]